Trial Profile

Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Biropepimut-S (Primary) ; Lenalidomide; Pneumococcal 7-valent CRM197 vaccine conjugate; Poly ICLC
Indications Myeloma
Focus Therapeutic Use

17 Dec 2018 Status changed from active, no longer recruiting to completed.
18 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
18 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com